Search results
FogPharma, Artbio join forces to design a different radiopharma drug
BioPharma Dive via Yahoo Finance· 10 hours agoThe biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based...
Drugmakers in Medicare Price Talks Spent Less on R&D Than on Shareholders, Marketing, Overhead:...
The Fiscal Times via Yahoo Finance· 5 days agoThe report says that the eight companies — Johnson & Johnson, Amgen, AstraZeneca, Bristol Myers...
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
Market Watch· 4 days agoNovartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia. The Swiss pharmaceutical company said ...
Analyst Report: Intellia Therapeutics, Inc.
Morningstar Research via Yahoo Finance· 5 hours agoIntellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with ...
Patient Preferences Drive Treatment Options for Early HS
Medscape· 2 days agoTreatment options for individuals with early-stage hidradenitis suppurativa (HS) vary depending on...
Drugmakers in Medicare negotiations spent more on shareholder payments and marketing than R&D last...
The Hill via Yahoo Finance· 6 days agoA new report from the center-left watchdog group Accountable US found that most major drugmakers...
The New Era of Life Sciences 2024
Newsweek· 1 day agoAs the legendary biotechnologist and biotech founder Robert Langer told us: 'What is truly thrilling is the potential for discoveries that are currently...
Earnings call: Harrow Inc. reports robust revenue growth in Q1 2024 By Investing.com
Investing.com· 3 hours agoHarrow, Inc. (ticker not provided), a prominent player in the ophthalmic pharmaceuticals industry,...
Q1 2024 Voyager Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 9 hours agoToby has hit the ground running, and we look forward to his leadership of our emerging clinical portfolio. In January, we announced an expansion of our relationship with Novartis< ...
Are Diabetes Drugs Set to Move OA Management Forward?
Medscape· 17 hours agoAre Diabetes Drugs Set to Move Osteoarthritis Management Forward? VIENNA — With the glucagon-like...
